GLPwatch
Papers (10410)
Page 152 of 174, ranked by citation count.
- Semaglutide may reduce cardiovascular disease and heart failure.
- Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.
- Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis.
- Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.
- Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.
- In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
- An Online Prescription for Hospitalisation: Euglycaemic Ketoacidosis Caused by an Online Tirzepatide Prescription.
- Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents With Variants in Monogenic Obesity-Related Genes.
- Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4.
- Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.
- Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.
- RFX6 maturity-onset diabetes of the young: clinical considerations and novel use of tirzepatide.
- Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga.
- Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements.
- Complete Skin Remission of Lichen Planus With Tirzepatide.
- Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.
- Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency.
- Evaluating Semaglutide's Protection in H/R - Injured AC16 Cardiomyocytes: Oxidative Stress, Inflammation, Apoptosis, and Autophagy Insights.
- Symmetrical drug-related intertriginous and flexural exanthema associated with tirzepatide.
- Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence.
- Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.
- Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.
- Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.
- Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
- New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.
- Web Exclusive. Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?
- Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany.
- [Effect of byetta on renal osmoregulatory function in patients with diabetes mellitus].
- Dulaglutide efficacy.
- Bronchopulmonary dysplasia induced by hyperoxia attenuated by A GLP-1 analog, Liraglutide, by regulating the ACE-2/Ang(1-7)/Mas receptor pathway.
- REWIND Diabetes for Octogenarians.
- A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.
- Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.
- Survodutide Once Weekly for the Treatment of Adults with Obesity.
- Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.
- Semaglutide in patients with hidradenitis suppurativa and obesity.
- Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study.
- Impact of Tirzepatide on FIB-4 in Patients with Type 2 Diabetes: A Comparison between GLP-1RA-naïve and GLP-1RA Switch Initiation in a Retrospective Cohort.
- Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide.
- Long-term effects of weight-reducing drugs in people with hypertension.
- Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine.
- [Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].
- [Obesity as a chronic disease: the key role of new therapies].
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
- A new indication for semaglutide (Wegovy).
- In response: Considerations regarding compounding pharmacies and GLP-1 agonists.
- Persistent Adipose Inflammation Despite Metabolic Recovery Reveals Tissue-Specific Immunomodulation by Tirzepatide.
- Once-Weekly Semaglutide in Adolescents with Obesity.
- Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control.
- Reply to "Revisiting Tirzepatide's Body Composition Model: Underestimated Fat-Free Mass Loss and Clinical Implications".
- Revisiting Tirzepatide's Body Composition Model: Underestimated Fat-Free Mass Loss and Clinical Implications.
- Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study.
- Correction: Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.
- D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice.
- Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.
- Lax oversight of semaglutide advertising could harm patients, warn critics.
- [Dulaglutide and liraglutide compared].
- Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity?
- Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide.
- The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction.